Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC

Through the neoadjuvant treatment with a combination of Pucotenlimab and Vorolanib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)

Trial Details

NCT ID

NCT07386158

Phase

PHASE2

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

Pucotenlimab combination with Vorolanib

Locations (sample)

Guangzhou, Other (Non U.s.), China|23.11667,113.25

Key Eligibility Criteria

Voluntarily sign a written informed consent form (ICF).
Age at the time of enrollment is between 18 years old and 85 years old, regardless of gender.
The physical fitness score of the Eastern Cooperative Oncology Group (ECOG) in the United States is 0 or 1.
Expected survival period ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →